Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates
Jul 28, 2022 19:06:35 GMT
thought013 and investobefree22 like this
Post by lookingforatenbagger on Jul 28, 2022 19:06:35 GMT
Zacks Equity Research, Thu, July 28, 2022 at 8:05 AM
"Pfizer (PFE) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.57%. A quarter ago, it was expected that this drug maker would post earnings of $1.66 per share when it actually produced earnings of $1.62, delivering a surprise of -2.41%."
Sadly nothing in the slide show on NGENLA beyond a its presence on a table noting EU approval. Did get a mention at the end in a list of drugs they expect to be marketing by the end of the year. Of course tehy are already marketing NGENLA in Japan, so .....
2/3s to 3/4s of the CC was on COVID related items.
"Pfizer (PFE) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.57%. A quarter ago, it was expected that this drug maker would post earnings of $1.66 per share when it actually produced earnings of $1.62, delivering a surprise of -2.41%."
Sadly nothing in the slide show on NGENLA beyond a its presence on a table noting EU approval. Did get a mention at the end in a list of drugs they expect to be marketing by the end of the year. Of course tehy are already marketing NGENLA in Japan, so .....
2/3s to 3/4s of the CC was on COVID related items.